-

Event

Bridging the Gap: New Collaborations to Drive Antimicrobial Innovation

This virtual event launched the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The fund will invest approximately $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections. 

Visit www.AMRActionFund.com to learn more.

Speakers (in order of appearance):

  • David Ricks, Chairman and CEO, Eli Lilly and Company
  • Michelle McMurry-Heath, President and CEO, BIO
  • Brandon Noble, former NFL player
  • Stephen J. Ubl, President and CEO, PhRMA
  • Ken Frazier, Chairman and CEO, Merck
  • Albert Bourla, Chairman and CEO, Pfizer
  • Priscilla VanderVeer, Vice President, PhRMA
  • ADM Brett P. Giroir, MD, Assistant Secretary for Health
  • Senator Bob Casey (D-PA)
  • Senator Bill Cassidy, MD (R-LA)
  • Scott Gottlieb, resident fellow, American Enterprise Institute – moderator
  • Helen Boucher, MD, board member and treasurer, Infectious Disease Society of America
  • Kathy Talkington, director, Health Programs, The Pew Charitable Trusts
  • Kevin Outterson, executive director and principal investigator, CARB-X
  • Ramani Varanasi, founder/president/CEO, X-Biotix
  • Michael Boyle, MD, president and CEO, Cystic Fibrosis Foundation

Bridging the Gap: New Collaborations to Drive Antimicrobial Innovation Event Video

A virtual event hosted by PhRMA, IFPMA and BIO announced the launch of the AMR Action Fund, a partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The fund will invest approximately $1 billion to ensure a robust and diverse pipeline of new medicines to treat drug-resistant infections.

Watch the video of the event here.